Skip to search formSkip to main contentSkip to account menu

CA1P

Known as: 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, 1,2-bis(dihydrogen Phosphate), Combretastatin A-1 bis(phosphate), Combretastatin A1 diphosphate 
The diphosphate prodrug of the stilbenoid combretastatin A1, originally isolated from the plant Combretum caffrum, with vascular-disrupting and… 
National Institutes of Health

Related topics

Related topics

3 relations
Microtubule ProcessNCIt Antineoplastic Agent TerminologyOxi 4503

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Vascular effects dominate solid tumor response to treatment with combretastatin A‐4‐phosphate
Vascular‐targeted therapeutics are increasingly used in the clinic. However, less is known about the direct response of tumor… 
Highly Cited
2008
Highly Cited
2008
Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity.
A novel class of combretastatins, modified at A-ring or both A- and B-rings, mainly by replacement with benzofuran or benzo[b… 
2007
2007
Synthesis and evaluation of 4/5-hydroxy-2,3-diaryl(substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anticancer agents.
A new series of 2,3-diaryl-4/5-hydroxy-cyclopent-2-en-1-one analogues replacing the cis double bond of combretastatin A-4 (CA-4… 
Highly Cited
2006
Highly Cited
2006
Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells
Combretastatin A-4 (CA-4), a natural stilbenoid isolated from Combretum caffrum, is a new vascular targeting agent (VTA) known… 
2005
2005
Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression.
Tubulin isotype distribution may play a role in the development of anti-cancer anti-tubulin drug resistance as well as in drug… 
Highly Cited
2001
Highly Cited
2001
Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
PURPOSE To compare the ability of combretastatin A-4 disodium phosphate (CA4DP) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA… 
2001
2001
Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy
Combretastatin A-4 prodrug (CA4P) is a new antitubulin agent currently in phase I/II clinical trials against solid tumors. We… 
Highly Cited
1999
Highly Cited
1999
Evaluation of Antivascular and Antimitotic Effects of Tubulin Binding Agents in Solid Tumor Therapy
Tubulin binding agents (TBAs) reduce tumor perfusion and inhibit mitosis of tumor cells in solid tumors, but it is not clear… 
Highly Cited
1998
Highly Cited
1998
Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug.
The (E)-stilbene isomer (2a) of the (Z)-combretastatin A-4 prodrug (1b) was efficiently prepared from (E)-combretastatin A-4 by a… 
Highly Cited
1998
Highly Cited
1998
Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug.
Combretastatin A-4 (1) as the phosphate ester prodrug (3d) is a potent antineoplastic and antiangiogenesis substance and is in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)